NASDAQ:LBPH Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free LBPH Stock Alerts $20.12 -1.87 (-8.50%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$20.02▼$22.2950-Day Range$17.00▼$22.8152-Week Range$3.60▼$28.15Volume156,226 shsAverage Volume388,334 shsMarket Capitalization$724.66 millionP/E RatioN/ADividend YieldN/APrice Target$43.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Longboard Pharmaceuticals alerts: Email Address Longboard Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside117.0% Upside$43.67 Price TargetShort InterestHealthy13.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.15Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.85) to ($2.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.73 out of 5 starsMedical Sector436th out of 925 stocksPharmaceutical Preparations Industry200th out of 430 stocks 4.5 Analyst's Opinion Consensus RatingLongboard Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLongboard Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Longboard Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted13.02% of the float of Longboard Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLongboard Pharmaceuticals has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Longboard Pharmaceuticals has recently decreased by 11.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLongboard Pharmaceuticals does not currently pay a dividend.Dividend GrowthLongboard Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LBPH. Previous Next 1.7 News and Social Media Coverage News SentimentLongboard Pharmaceuticals has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Longboard Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for LBPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Longboard Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.64% of the stock of Longboard Pharmaceuticals is held by insiders.Percentage Held by Institutions63.28% of the stock of Longboard Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Longboard Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Longboard Pharmaceuticals are expected to decrease in the coming year, from ($1.85) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longboard Pharmaceuticals is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longboard Pharmaceuticals is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongboard Pharmaceuticals has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Longboard Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubMost important medical advance in 100 yearsThis is going to dramatically alter medicine forever. Keep in mind, creating a new effective drug in the past took up to 10 years and could cost up to $12 billion. But now, with artificial intelligence, it could take months and cost a fraction of that amount.Watch my new presentation detailing the opportunity About Longboard Pharmaceuticals Stock (NASDAQ:LBPH)Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Read More LBPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LBPH Stock News HeadlinesMay 11, 2024 | americanbankingnews.comHC Wainwright Analysts Lower Earnings Estimates for Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH)May 8, 2024 | americanbankingnews.comLongboard Pharmaceuticals (NASDAQ:LBPH) Given "Buy" Rating at HC WainwrightMay 11, 2024 | Banyan Hill Publishing (Ad)CEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Longboard Pharmaceuticals Amidst Positive Clinical Progress and Market Potential for BexicaserinMay 7, 2024 | americanbankingnews.comLongboard Pharmaceuticals' (LBPH) Overweight Rating Reaffirmed at Cantor FitzgeraldMay 6, 2024 | businesswire.comLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 6, 2024 | americanbankingnews.comLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Given Average Recommendation of "Buy" by AnalystsMay 5, 2024 | americanbankingnews.comLongboard Pharmaceuticals (NASDAQ:LBPH) Trading Down 5.7%May 11, 2024 | Banyan Hill Publishing (Ad)CEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.May 5, 2024 | americanbankingnews.comLongboard Pharmaceuticals (NASDAQ:LBPH) PT Raised to $34.00May 4, 2024 | finance.yahoo.comLongboard Pharmaceuticals Inc. (LBPH) Q1 2024 Earnings: Financial and Strategic DevelopmentsMay 3, 2024 | msn.comLongboard Pharmaceuticals EPS of -$0.42 beats by $0.07May 3, 2024 | americanbankingnews.comLongboard Pharmaceuticals (NASDAQ:LBPH) Shares Gap Up to $21.30May 3, 2024 | americanbankingnews.comLongboard Pharmaceuticals (NASDAQ:LBPH) Now Covered by Robert W. BairdMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed on Longboard Pharmaceuticals with Promising Bexicaserin Developments and Regulatory Milestones AheadMay 2, 2024 | investorplace.comLBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024May 2, 2024 | businesswire.comLongboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 2, 2024 | msn.comBaird Initiates Coverage of Longboard Pharmaceuticals (LBPH) with Outperform RecommendationApril 17, 2024 | markets.businessinsider.comBexicaserin’s Promising Future: Buy Rating Justified by Strong Clinical Data and Potential Blockbuster StatusApril 3, 2024 | businesswire.comLongboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15April 2, 2024 | businesswire.comLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 27, 2024 | finance.yahoo.comLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50%March 16, 2024 | finance.yahoo.comLBPH Apr 2024 17.500 putMarch 14, 2024 | finance.yahoo.comLongboard Pharmaceuticals Inc Reports Full Year 2023 Financial ResultsMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Longboard Pharmaceuticals’ Bexicaserin Shows Promising Efficacy and Strategic MilestonesMarch 12, 2024 | benzinga.comRecap: Longboard Pharmaceuticals Q4 EarningsMarch 12, 2024 | businesswire.comLongboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate UpdatesSee More Headlines Receive LBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/11/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LBPH CUSIPN/A CIK1832168 Webwww.longboardpharma.com Phone619-592-9775FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$43.67 High Stock Price Target$60.00 Low Stock Price Target$32.00 Potential Upside/Downside+117.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.87% Return on Assets-46.04% Debt Debt-to-Equity RatioN/A Current Ratio31.43 Quick Ratio31.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.71 per share Price / Book2.31Miscellaneous Outstanding Shares36,020,000Free Float34,346,000Market Cap$724.72 million OptionableOptionable Beta1.25 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Kevin R. Lind (Age 48)President, CEO, Secretary & Director Comp: $1.07MMs. Brandi L. Roberts CPA (Age 50)M.B.A., Executive VP & CFO Comp: $662.65kDr. Randall E. Kaye M.D. (Age 62)Executive VP & Chief Medical Officer Comp: $717.95kMr. Chadwick J. Orevillo MPHExecutive VP & Head of OperationsMegan E. KnightVP & Head of Investor RelationsMr. Steven W. Spector J.D. (Age 59)Executive VP, Head of Business Development & General Counsel Dr. Anne M. Danks Ph.D.VP & Head of Nonclinical Research & DevelopmentMr. Gus CardenasVP & Head of Quality AssuranceDr. Marco Peters Ph.D.VP & Head of Translational ScienceDr. Dewey McLin Ph.D.VP & Head of Medical AffairsMore ExecutivesKey CompetitorsSage TherapeuticsNASDAQ:SAGEPliant TherapeuticsNASDAQ:PLRXY-mAbs TherapeuticsNASDAQ:YMABTango TherapeuticsNASDAQ:TNGXEvolusNASDAQ:EOLSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 937,998 shares on 5/10/2024Ownership: 4.787%Lord Abbett & CO. LLCBought 475,179 shares on 5/9/2024Ownership: 1.319%Swiss National BankBought 42,300 shares on 5/7/2024Ownership: 0.117%Sei Investments Co.Bought 19,861 shares on 5/7/2024Ownership: 0.055%SG Americas Securities LLCBought 6,102 shares on 5/7/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions LBPH Stock Analysis - Frequently Asked Questions Should I buy or sell Longboard Pharmaceuticals stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LBPH shares. View LBPH analyst ratings or view top-rated stocks. What is Longboard Pharmaceuticals' stock price target for 2024? 6 analysts have issued 12 month price targets for Longboard Pharmaceuticals' stock. Their LBPH share price targets range from $32.00 to $60.00. On average, they anticipate the company's share price to reach $43.67 in the next year. This suggests a possible upside of 117.0% from the stock's current price. View analysts price targets for LBPH or view top-rated stocks among Wall Street analysts. How have LBPH shares performed in 2024? Longboard Pharmaceuticals' stock was trading at $6.03 on January 1st, 2024. Since then, LBPH stock has increased by 233.7% and is now trading at $20.12. View the best growth stocks for 2024 here. When is Longboard Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our LBPH earnings forecast. How were Longboard Pharmaceuticals' earnings last quarter? Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) issued its quarterly earnings results on Tuesday, March, 12th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.02. What ETFs hold Longboard Pharmaceuticals' stock? ETFs with the largest weight of Longboard Pharmaceuticals (NASDAQ:LBPH) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). When did Longboard Pharmaceuticals IPO? Longboard Pharmaceuticals (LBPH) raised $75 million in an IPO on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor acted as the underwriters for the IPO. Who are Longboard Pharmaceuticals' major shareholders? Longboard Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.79%), Jennison Associates LLC (2.62%), Lord Abbett & CO. LLC (1.32%), Swiss National Bank (0.12%), Sei Investments Co. (0.06%) and Quantbot Technologies LP (0.04%). View institutional ownership trends. How do I buy shares of Longboard Pharmaceuticals? Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LBPH) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithMost important medical advance in 100 yearsThe Oxford ClubA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchMissed NVDA? Buy this AI stock NOWChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longboard Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
